Skip To Main Content
Salvatore Siena on Muck Rack

Salvatore Siena

As seen in: Nature, Educational Studies, The Lancet, Cell Press, Healio, HemOnc Today, OncLive, Targeted Oncology, Cancer Treatment Reviews, Oncoinfo
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Salvatore

Contact Salvatore, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Absence of co-occurrence between HER2 amplification and dMMR/MSI in a large multicentric colorectal cancer cohort

|
By Annalice Gandini, Federica Tosi, Luca Carmisciano, Federica Grillo, Luca Mastracci, Chiara Pirrone, Simone Nardin, Valentino Martelli, Alessandro Pastorino, Gianluca Mauri, Alessio Amatu, Erica Francesca Bonazzina, Katia Bencardino, Salvatore Siena, Stefania Sciallero, Andrea Sartore-Bianchi, Alberto Puccini, Silvia Puglisi, Daniele Piscazzi, Maria Costanza Aquilano
| Nature Verified
Abstract Mismatch repair deficiency (dMMR)/Microsatellite instability (MSI) plays a central role in colorectal cancer (CRC) as a predictive and prognostic biomarker and as a “red flag” for diagnosis of Lynch Syndrome (LS). HER2 is emerging as a therapeutic target and clinical trials are ongoing. Several reports suggested that HER2 amplification could be mutually exclusive with dMMR/MSI, which is mostly associated with HER2 mutations or other alterations.
Open in Who Shared Issue with article?

Author Correction: The genomic landscape of response to EGFR blockade in colorectal cancer - Nature

|
By Andrea Bertotti, Eniko Papp, Sian Jones Verified, Vilmos Adleff, Valsamo Anagnostou, Barbara Lupo, Mark Sausen, Jillian Phallen, Carolyn Hruban, Collin Tokheim, Noushin Niknafs, Monica C Nesselbush, Francesco Sassi, Francesca Cottino, Giorgia Migliardi, Eugenia R. Zanella, Dario Ribero, Nadia Russolillo, Alfredo Mellano, Andrea Muratore Verified, Gianluca Paraluppi, Mauro Salizzoni, Silvia Marsoni, Qing Li, Rachel Karchin, Robert B. Scharpf, Andrea Sartore-Bianchi, Salvatore Siena, Livio Trusolino, Victor E. Velculescu, Karli Lytle, Michael Kragh, Johan Lantto, Andrea Cassingena
| Nature Verified
Correction to: Nature https://doi.org/10.1038/nature14969 Published online 30 September 2015 In Extended Data Fig. 8 of this article, a micrograph shown in the left column (panel AZD) was inadvertently duplicated during figure preparation. The intended image was meant to show phospho-ERK (P-ERK) levels in a MAP2K1-mutant patient-derived xenograft (PDX) exposed to the MEK inhibitor AZD6244 (AZD). However, this image was accidentally overlaid with a micrograph from Extended Data Fig.
Open in Who Shared Issue with article?

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis - Nature Communications

|
By John Strickler, Salvatore Siena, Thierry Andre, Thierry André, Kimmie Ng, Christos Fountzilas, Pashtoon Murtaza Kasi, Heinz-Josef Lenz, Elena Elez, Chiara Cremolini
| Nature Verified
Abstract MOUNTAINEER was a multicenter, open-label, phase 2 trial (NCT03043313) that evaluated the efficacy and safety of tucatinib plus trastuzumab, a dual HER2-targeted chemotherapy-free regimen. Patients were included if they had chemotherapy-refractory, HER2+, RAS wild-type unresectable or metastatic colorectal cancer. This final analysis reports updated efficacy and safety after a median follow-up of 32.4 months.
Open in Who Shared Issue with article?
See all 21 licensed articles (23 Total)